More pos­i­tive PhI­II da­ta set stage for Scynex­is' vagi­nal yeast in­fec­tion drug ap­proval

Months af­ter un­veil­ing da­ta that showed its lead ex­per­i­men­tal com­pound, ibrex­a­fungerp, helped pa­tients with vagi­nal yeast in­fec­tions, an­ti­fun­gal drug de­vel­op­er Scynex­is is one step clos­er to the fin­ish line with a sec­ond pos­i­tive piv­otal tri­al.

The com­pa­ny — which burst in­to the zeit­geist as one of the few com­pa­nies test­ing a Can­di­da au­ris ther­a­py (the same drug ibrex­a­fungerp) in hu­man tri­als — is gear­ing up to sub­mit a mar­ket­ing ap­pli­ca­tion in the sec­ond half of this year, for what it claims is the first and on­ly oral, non-azole treat­ment for vagi­nal yeast in­fec­tions, a con­di­tion that af­fects three out of four women across their life­times but has lim­it­ed treat­ment op­tions.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.